产品名称
Anti-BDNF Mouse mAb (35928.11), lyophilized, clone 35928.11, Calbiochem®
biological source
mouse
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
35928.11, monoclonal
form
lyophilized
does not contain
preservative
species reactivity
human
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
avoid repeated freeze/thaw cycles
dilution
(ELISA (0.5-1 µg/mL)
Immunoblotting (1-2 µg/mL)
Immunohistochemistry (5-15 µg/mL)
Neutralization Studies )
isotype
IgG1
shipped in
ambient
storage temp.
−20°C
target post-translational modification
unmodified
Quality Level
Gene Information
human ... BDNF(627)
Application
ELISA (0.5-1 µg/ml)
Immunoblotting (1-2 µg/ml)
Immunohistochemistry (5-15 µg/ml)
Neutralization Studies (see comments)
Immunoblotting (1-2 µg/ml)
Immunohistochemistry (5-15 µg/ml)
Neutralization Studies (see comments)
Disclaimer
Toxicity: Standard Handling (A)
General description
Anti-BDNF, mouse monoclonal, clone 35928.11, recognizes the ~20 kDa BDNF protein in brain extracts. It is validated for ELISA, Western blotting, immunohistochemistry, and neutralization studies.
Immunoaffinty purified mouse monoclonal antibody. Recognizes the ~20 kDa BDNF protein.
Recognizes the ~20 kDa BDNF protein in brain extracts. Clone 35928.11 was selected based on its ability to neutralize the biological activity of human recombinant BDNF.
Immunogen
recombinant protein consisting of amino acids 129-247 of human BDNF
Other Notes
Riccio, A., et al. 1997. Science277 1097.
Sendtner, M., et al. 1996. Neurochem. Res.21, 831.
Barbacid, M. 1995. Ann. N.Y. Acad. Sci.766, 442.
Gotz, R., et al. 1994. Nature372, 266.
Snider, W.D. 1994. Cell77, 627.
Snider, W.D., et al. 1992. J. Neurobiol.23, 1231.
Sendtner, M., et al. 1996. Neurochem. Res.21, 831.
Barbacid, M. 1995. Ann. N.Y. Acad. Sci.766, 442.
Gotz, R., et al. 1994. Nature372, 266.
Snider, W.D. 1994. Cell77, 627.
Snider, W.D., et al. 1992. J. Neurobiol.23, 1231.
The full-length sequence for BDNF can be found under accession number NP_001700. This antibody has been selected for its ability to neutralize the biological activity of human recombinant BDNF. The exact concentration of antibody required to neutralize human recombinant BDNF activity is dependent on the cytokine concentration, cell type, growth conditions, and the type of activity studied. Suggested neutralization concentration required to yield one-half maximal inhibition of BDNF activity is approximately 5-15 µg/ml in the presence of 2.5 ng/ml of human recombinant BDNF, in a neuron survival assay using embryonic chick dorsal root ganglia neurons. The detection limit for human recombinant BDNF is ~300 ng/lane under non-reducing and reducing conditions. The detection for human recombinant BDNF is ~12.5 ng/ml. Based on immunoblotting and ELISA, this antibody exhibits less than 2% cross-reactivity with human recombinant β-NGF, human recombinant NT-3, and human recombinant NT-4. Antibody should be titrated for optimal results in individual systems.
Physical form
Lyophilized from PBS, 5% trehalose.
Preparation Note
We recommend resuspending the lyophilized antibody with sterile PBS, pH 7.4, or sterile 20 mM Tris-saline (20 mM Tris containing 0.15 M NaCl), pH 7.4, to yield a final concentration of 100 µg/ml. Following reconstitution, aliquot and freeze (-20°C).
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
未找到合适的产品？
试试我们的产品选型工具.
存储类别
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
A Markham et al.
The European journal of neuroscience, 20(5), 1189-1196 (2004-09-03)
Brain-derived neurotrophic factor (BDNF) governs both the selective survival of neurons during development and the experience-based regulation of synaptic strength throughout life. BDNF produced a concentration-dependent increase in the respiratory control index (RCI, a measure of the efficiency of respiratory
Natalia A Stefanova et al.
Aging, 8(11), 2713-2733 (2016-10-18)
Mitochondrial aberrations are observed in human Alzheimer's disease (AD) and in medical conditions that increase the risk of this disorder, suggesting that mitochondrial dysfunction may contribute to pathophysiology of AD. Here, using OXYS rats that simulate key characteristics of sporadic
Tinmarla F Oo et al.
Molecular and cellular neurosciences, 41(4), 440-447 (2009-05-05)
Brain-derived neurotrophic factor (BDNF) was the first purified molecule identified to directly support the development of mesencephalic dopamine neurons. However, its physiologic role has remained unknown. Based on patterns of expression, it is unlikely to serve as a target-derived neurotrophic
Hugo Talbot et al.
Scientific reports, 10(1), 12572-12572 (2020-07-30)
Evading apoptosis and sustained survival signaling pathways are two central hallmarks of B-cell chronic lymphocytic leukemia (B-CLL) cells. In this regard, nurse-like cells (NLC), the monocyte-derived type 2 macrophages, deliver stimulatory signals via B-cell activating factor (BAFF), a proliferation-inducing ligand
Milena Penkowa et al.
Journal of neuroscience research, 79(4), 522-534 (2004-12-23)
We examined metallothionein (MT)-induced neuroprotection during kainic acid (KA)-induced excitotoxicity by studying transgenic mice with MT-I overexpression (TgMT mice). KA induces epileptic seizures and hippocampal excitotoxicity, followed by inflammation and delayed brain damage. We show for the first time that
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持